PolyPid Inks $320M+ D-PLEX100 Deal with Azurity, Adding Royalties and Manufacturing Revenue
PYPD sits 58% above its 52-week low of $3.06.
Summary
PolyPid signed a transformative licensing deal with Azurity for D-PLEX100 in the U.S. and Canada, worth over $320M in milestones plus tiered royalties and manufacturing revenue. The deal includes $30M upfront—$15M on signing and $15M on expected FDA NDA acceptance in August—immediately funding operations. Azurity, a specialty pharma with a hospital-focused commercial model and recent bowel-preparation franchise acquisition, is an ideal partner for the colorectal surgery indication. Beyond the initial label, Azurity will fund expansion into cardiac, orthopedic, and breast reconstruction surgeries, growing the addressable market without PolyPid capital. PolyPid retains its Kynatrix delivery platform and can now advance next-gen programs like a GLP-1 candidate for diabetes and obesity. This follows the NDA submission in June and shareholder approvals in July, marking a rapid transition to commercial-stage with multiple near-term catalysts.
At the time of this announcement, PYPD was trading at $4.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $98.3M. The 52-week trading range was $3.06 to $5.73. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: FinanceWire.